Literature DB >> 3839736

A computer program package for relative survival analysis.

T Hakulinen, K H Abeywickrama.   

Abstract

A computer program package has been constructed for use in patient survival analyses for chronic diseases based on aggregated data. The central concept of the analyses--the relative survival rate--is the ratio of the observed survival rate of the patients to the survival rate expected in a group in the general population similar to the group of patients at the beginning of the follow-up (interval), with respect to age, sex and calendar time. This quantity is used to measure patient survival adjusted for the effect of mortality attributable to the competing risks of death without employing information on causes of death of individual patients. The package contains three alternative methods of estimating the relative survival rates, two different ways of estimating the expectation of life for the patients, and five methods of testing the relative survival patterns using information on the whole follow-up period. Conventional survival and competing risk analysis can also be performed with the package. It is hoped that the package will facilitate standardization of statistical methodology and terminology in long-term survival studies for chronic diseases.

Entities:  

Mesh:

Year:  1985        PMID: 3839736     DOI: 10.1016/0010-468x(85)90011-x

Source DB:  PubMed          Journal:  Comput Programs Biomed        ISSN: 0010-468X


  45 in total

1.  Cancer survival in Estonian migrants to Sweden.

Authors:  B Nilsson; E Gustavson-Kadaka; T Hakulinen; T Aareleid; M Rahu; T Dyba; S Rotstein
Journal:  J Epidemiol Community Health       Date:  1997-08       Impact factor: 3.710

2.  Survival in stomach cancer is improving: results of a nationwide population-based Swedish study.

Authors:  L E Hansson; P Sparén; O Nyrén
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

3.  Estimation and projections of stomach cancer trends in Italy.

Authors:  R Capocaccia; R De Angelis; L Frova; M Sant; E Buiatti; G Gatta; A Micheli; F Berrino; A Barchielli; E Conti
Journal:  Cancer Causes Control       Date:  1995-07       Impact factor: 2.506

4.  Cervical smears--an opportunity for disinvestment?

Authors:  M T Spence; C Woodman; S Collins; B Donnelly; M Desai
Journal:  Br J Gen Pract       Date:  1996-09       Impact factor: 5.386

5.  Survival rates from interval cancer in NHS breast screening programme.

Authors:  S Collins; C B Woodman; A Threlfall; P Prior
Journal:  BMJ       Date:  1998-03-14

6.  Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study.

Authors:  Kee Wook Jung; Nicholas J Talley; Yvonne Romero; David A Katzka; Cathy D Schleck; Alan R Zinsmeister; Kelly T Dunagan; Lori S Lutzke; Tsung-Teh Wu; Kenneth K Wang; Mary Frederickson; Debra M Geno; G Richard Locke; Ganapathy A Prasad
Journal:  Am J Gastroenterol       Date:  2011-04-12       Impact factor: 10.864

7.  Measuring social class differences in cancer patient survival: is it necessary to control for social class differences in general population mortality? A Finnish population-based study.

Authors:  P W Dickman; A Auvinen; E T Voutilainen; T Hakulinen
Journal:  J Epidemiol Community Health       Date:  1998-11       Impact factor: 3.710

8.  Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period.

Authors:  A Członkowska; B Tarnacka; T Litwin; J Gajda; M Rodo
Journal:  J Neurol       Date:  2005-03-02       Impact factor: 4.849

9.  Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989.

Authors:  R H A Verhoeven; W J Louwman; E L Koldewijn; T B J Demeyere; J W W Coebergh
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

10.  Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995-2004.

Authors:  Bärbel Jung; Lars Påhlman; Robert Johansson; Erik Nilsson
Journal:  BMC Cancer       Date:  2009-02-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.